Commentary
Our growing understanding of the natural history and pathogenesis of MAFLD and the predominant role of metabolic dysfunction in this disease have evoked efforts to redefine fatty liver disease.
As pointed out by J. Alharthi and M. Eslam (Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Australia), this redefinition process for improving our ability to deliver optimal multidisciplinary care will lead to improved outcomes for these patients and a decreased burden on healthcare systems.
